Name

Dr Ben Wolf, MD, PhD

Title

Chief Medical Officer

Ben is our Chief Medical Officer. He brings nearly 20 years of biopharmaceutical experience including expertise in precision oncology and advancing novel therapeutic programs from discovery through to regulatory approval.

Ben joined Isomorphic Labs from Relay Therapeutics, where he led the company's clinical trials and advanced multiple molecules into pivotal testing as Chief Medical Officer. Prior to this, he was CMO at KSQ Therapeutics, where he advanced a CRISPR-based cancer therapeutic pipeline.

He has also held senior clinical development roles at Blueprint Medicines, where he led multiple precision medicine programs for kinase inhibitors to successful registration, including Ayvakit™ and Gavreto™.

Ben has authored more than 40 peer-reviewed publications and is an inventor on multiple patents related to drug discoveries.

He earned his B.S. from Union College and M.D. and Ph.D. in biochemistry from the University of Virginia, completing medical training in internal medicine and medical oncology at the University of California at San Diego.

“Isomorphic Labs' unified drug design engine enables our team to tackle multiple therapeutic areas and drug modalities, opening up new avenues for treating diseases. To maximise the impact of our work, we need to translate our research into transformational treatments for patients globally, and I’m excited to be leading our work in this area.”